Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial.

Authors : de Angelis C, Ignatiadis M, Piccart-Gebhart M
Year : 2020
Journal : Ann Transl Med
Volume : 8
Pages : 1338

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.

Authors : Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M, Piccart-Gebhart M, Van Tienhoven G, Mansel R, Wildiers H, Bottomley A
Year : 2020
Journal : Eur J Cancer
Volume : 125
Pages : 69-82

Early prediction of neoadjuvant treatment outcome in locally advanced breast cancer using parametric response mapping and radial heterogeneity from breast MRI.

Authors : Drisis S, El Adoui M, Flamen P, Benjelloun M, de Wind R, Paesmans M, Ignatiadis M, Bali MA, Lemort M
Year : 2020
Journal : J Magn Reson Imaging
Volume : 51
Pages : 1403-1411

Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations.

Authors : Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Berlière M, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge AH, Caron O, Saule C, Del Mastro L, Peccatori FA, Azim HA Jr
Year : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 3012-3023

CANCER DU SEIN AVEC MÉTASTASE INHABITUELLE AU NIVEAU VÉSICAL : RAPPORT DE CAS ET REVUE SYSTÉMATIQUE DE LA LITTÉRATURE

Authors : Marcoux D, Ignatiadis M, Paesmans M, Awada A
Year : 2019
Journal : Rev Med Brux
Volume : 40(3)
Pages : 148-159

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Authors : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Authors : Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, Van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K
Year : 2019
Journal : Crit Rev Oncol Hematol
Volume : 134
Pages : 39-45

Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.

Authors : Rossi G, Ignatiadis M
Year : 2019
Journal : Cancer Res
Volume : 79
Pages : 2798-2804

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Authors : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 304

Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?

Authors : Brandão M, Coens C, Ignatiadis M
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1677-1681

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Authors : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Year : 2019
Journal : Support Care Cancer
Volume : 27
Pages : 1163-1170

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Authors : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Year : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Authors : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 86-94

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.

Authors : Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 69-77

CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?

Authors : Brandão M, Ignatiadis M
Year : 2018
Journal : Ann Oncol
Volume : 29(12)
Pages : 2274-2278

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Authors : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Year : 2018
Journal : Ann Oncol
Volume : 29(8)
Pages : 1777-1783

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Authors : Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, dHollander K, Pantel K
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(6)
Pages : 560-567

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.

Authors : Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, Delbaere A, Tkint de Roodenbeke D, de Azambuja E, Ignatiadis M, Demeestere I
Year : 2018
Journal : Ann Oncol
Volume : 29(1)
Pages : 237-243

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.

Authors : Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, Jensen MB, Gelber S, Del Grande M, Ignatiadis M, de Azambuja E, Paesmans M, Peccatori FA, Azim HA Jr
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(4)
Pages : 426-429

Total choline quantification measured by 1H MR spectroscopy as early predictor of response after neoadjuvant treatment for locally advanced breast cancer: The impact of immunohistochemical status.

Authors : Drisis S, Flamen P, Ignatiadis M, Metens T, Chao SL, Chintinne M, Lemort M
Year : 2018
Journal : J Magn Reson Imaging
Volume : 48(4)
Pages : 982-993